AbbVie’s Venclexta Fails In Combo AML Trial
Pfizer’s Daurismo May Benefit From Venclexta’s VIALE-C Setback
AbbVie’s Venclexta failed to show a significant improvement in the primary endpoint of overall survival in the Phase III VIALE-C for AML, but there was numerical improvement. Its setback is good news for Pfizer’s rival Daurismo, analysts said.
